Company Overview
Company Type: Public Company
Website: algernonpharmaceuticals.com
Number of Employees: -
Ticker: AGN (CNSX)
Year Founded: 2015


Business Description
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada, Australia, and New Zealand. The company’s pipeline includes Ifenprodil, which completed Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in preclinical stage for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which has completed preclinical stage for the treatment of strokes. The company was formerly known as “Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
2.3
EBITDA
(6.2)
Total Enterprise Value
1.9
TEV/EBITDA
NM
EBIT
(6.2)
Cash & ST Invst.
0.4
P/Diluted EPS Before Extra
NM
Net Income
(6.5)
Total Debt
0.0
Price/Tang BV
NM
Total Assets
6.1


Currency in CAD in mm, LTM as of May-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Moreau, Christopher J.
CEO & Director
Kinley, James F.
Chief Financial Officer
Bryan, Christopher 
Vice President of Research & Operations

Key Board Members
Name
Title
Bloomfield, Harold J. F.
Independent Chairman of the Board
Moreau, Christopher J.
CEO & Director
Attariwala, Rajpaul 
Independent Director
Brody, David L.
Member of Medical & Scientific Advisory Board
Dicpinigaitis, Peter 
Medical Consultant of Chronic Cough Research Prgm. & Member of Medical and Scientific Advisory Board
Frecska, Ede 
Member of Medical & Scientific Advisory Board
Gutman, Howard W.
Director
Kolb, Martin 
Member of Medical & Scientific Advisory Board
Maas, Andrew 
Member of Medical & Scientific Advisory Board
Nagy, Zoltan 
Member of Medical & Scientific Advisory Board
Nutt, David John
Member of Medical & Scientific Advisory Board
Rudd, Anthony 
Member of Medical & Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
601 West Broadway Suite 400 | Vancouver, BC | V5Z 4C2 | Canada

Current and Pending Investors
AlphaNorth Asset Management, Novotech (Australia) Pty Limited

Prior Investors
BullRun Capital Inc. (Kulwant Malhi)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.15
Market Cap (mm)
2.3
Open
 0.15
Shares Out. (mm)
15.8
Previous Close
 0.15
Float %
78.9%
Change on Day
0.01
Shares Sold Short (mm)
-
Change % on Day
7.4%
Dividend Yield %
-
Day High/Low
 0.15/ 0.15
Diluted EPS Excl. Extra Items
(0.68)
52 wk High/Low
 0.96/ 0.13
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0010
Avg 3M Dly Vlm (mm)
0.01
Beta 5Y
0.57


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
CNSX:AGN - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
NASH Pharmaceuticals Inc.
NASH Pharmaceuticals Inc. develops novel cannabinoid-related and other therapies for patients diagnosed with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH). The company offers combination of patented drugs including CBD counters diet-induced obesity by enhancing metabolism and energy expenditure by which therapeutic effect is mediated through effects in both the liver and the brain and the liver enzyme levels are reversed. The company has a partnership with Yissum. The company is based in Vancouver, Canada. As of October 9, 2018, NASH Pharmaceuticals Inc. operates as a subsidiary of Breathtec Biomedical, Inc.

United States and Canada
Biotechnology
-
-
-
Breathtec Biomedical, Inc.
As of October 26, 2015, PBA Acquisitions Corp. was acquired by Breathtec Biomedical Inc. Breathtec Biomedical, Inc. is a development stage company focusing on development and commercialization of handheld mass spectrometers for breath testing to detect diseases. The company was incorporated in 2015 and is based in Vancouver, Canada.

United States and Canada
Health Care Equipment
-
0.00
0.00
Algernon Neuroscience Inc.
Algernon Neuroscience Inc. engages in the DMT research and development program. It is developing DMT Fumarate (1:1), a cGMP API product of the psychedelic compound N,N-dimethyltryptamine (DMT) that is in Phase 1 clinical trials for use in the treatment of stroke. The company was incorporated in 2022 and is based in Vancouver, Canada. Algernon Neuroscience Inc. operates as a subsidiary of Algernon Pharmaceuticals Inc.

United States and Canada
Pharmaceuticals
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-14-2023
-
Private Placement
Target
Algernon Pharmaceuticals Inc. (CNSX:AGN)


0.16
Mar-21-2023
Apr-27-2023
Public Offering
Target
Algernon Pharmaceuticals Inc. (CNSX:AGN)


0.87
Dec-23-2022
-
Public Offering
Target
Algernon Pharmaceuticals Inc. (CNSX:AGN)


3.68
Aug-23-2022
Aug-23-2022
Private Placement
Target
Algernon Pharmaceuticals Inc. (CNSX:AGN)
AlphaNorth Asset Management

-
Aug-18-2022
Aug-22-2022
Private Placement
Target
Algernon Pharmaceuticals Inc. (CNSX:AGN)


1.07
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-02-2023
Annual General Meeting
Algernon Pharmaceuticals Inc., Annual General Meeting, Aug 02, 2023
Jul-14-2023
Private Placements
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding
Jun-27-2023
Considering Multiple Strategic Alternatives
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities
Jun-10-2023
Company Conference Presentations
Algernon Pharmaceuticals Inc. Presents at American Cough Conference, Jun-10-2023 02:05 PM
May-31-2023
Product-Related Announcements
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Competitors
Menssana Research Inc.

M&A Advisors
Locke Lord LLP


Advisors
Most Recent Auditor
Smythe LLP
M&A Advisors
Locke Lord LLP
Private Placement Advisors
Research Capital Corporation
Public Offering Advisors
McMillan LLP, Smythe LLP
Key development Advisor
Maxim Group LLC


Most Recent Auditor
Smythe Ratcliffe


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Aug 29, 2023 01:52 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
52
GlobalData

Aug 29, 2023 01:47 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
25
GlobalData

May 17, 2023 06:27 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
25
GlobalData

May 17, 2023 05:34 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
52
GlobalData

Feb 13, 2023 05:28 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
25
GlobalData

Feb 10, 2023 04:18 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
48
GlobalData

Dec 27, 2022 03:04 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
83
Research Capital Corporation
Uddin, Andre
Nov 30, 2022 05:46 AM
AGN
Q4 - One Step At A Time - Lowering TP
Reports
6
GlobalData

Oct 26, 2022 06:05 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
25
GlobalData

Aug 29, 2022 09:59 AM
AGN
Algernon Pharmaceuticals Inc (AGNPF.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
25


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


AlphaNorth Asset Management

3,002,880

19.03

0.4

May-31-2023


Attariwala M.D., Ph.D., Rajpaul 

114,760

0.73

0.0

May-05-2023


Moreau, Christopher J.

108,102

0.69

0.0

May-05-2023


Eldee Foundation, Endowment Arm

48,000

0.30

0.0

May-05-2023


Bloomfield B.A., KJ.ST.J., LL.B., M.B.A., Q.C., Harold J. F.

48,000

0.30

0.0

May-05-2023


Gutman, Howard W.

21,512

0.14

0.0

Mar-14-2023


Williams M.B.A., Ph.D., Mark 

18,132

0.11

0.0

May-05-2023


Kinley C.A., CPA, James F.

10,992

0.07

0.0

May-05-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
AlphaNorth Asset Management
3,002,880
1,733,240
Attariwala M.D., Ph.D., Rajpaul 
114,760
52,080
Moreau, Christopher J.
108,102
36,034
Eldee Foundation, Endowment Arm
48,000
24,000
Bloomfield B.A., KJ.ST.J., LL.B., M.B.A., Q.C., Harold J. F.
48,000
14,668
Kinley C.A., CPA, James F.
10,992
5,496

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-07
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
ENP Newswire
Sep-06
AGN Algernon receives U.S. patent for repirinast drug
Canada StockWatch


Company Coverage
This company is not on any Coverage List.

Products
Bemethyl (Future), Bromantane (Future), Emoxypine, Ifenprodil (Future), N,N-Dimethyltryptamine (Future), NP-251 (Future), POC Breathalyzer Device, Repirinast (Future)


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-06-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
73 KB
Aug-08-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
78 KB
Jul-28-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
Interim Financial Statements
321 KB
Jul-14-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
73 KB
Jun-28-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
79 KB
Jun-19-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
Notice of the Meeting and Record Date
700 KB
Jun-12-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
Securities Acquisition Filings
30 KB
Jun-06-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
73 KB
Jun-05-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
76 KB
May-31-2023
Algernon Pharmaceuticals Inc. (CNSX:AGN)
SEDAR
News Releases
72 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Moreau, Christopher J. (CEO & Director)
May-05-2023
Common Shares
36,034
9,218
Derivative Exercise and Retained Stock
50.00
Multiple
Bloomfield B.A., KJ.ST.J., LL.B., M.B.A., Q.C., Harold J. F. (Independent Chairman of the Board)
May-05-2023
Common Shares
33,332
8,527
Derivative Exercise and Retained Stock
227.24
Multiple
Eldee Foundation, Endowment Arm
May-05-2023
Common Shares
24,000
6,139
Derivative Exercise and Retained Stock
100.00
Multiple
Kinley C.A., CPA, James F. (Chief Financial Officer)
May-05-2023
Common Shares
5,496
1,406
Derivative Exercise and Retained Stock
100.00
Multiple
Attariwala M.D., Ph.D., Rajpaul  (Independent Director)
May-05-2023
Common Shares
52,080
13,323
Derivative Exercise and Retained Stock
83.09
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bloomfield, Harold J. F.
Independent Chairman of the Board
-
-

Moreau, Christopher J.
CEO & Director
604.398.4175x701
-
chris@algernonpharmaceuticals.com
Attariwala, Rajpaul 
Independent Director
-
-

Brody, David L.
Member of Medical & Scientific Advisory Board
-
-

Dicpinigaitis, Peter 
Medical Consultant of Chronic Cough Research Prgm. & Member of Medical and Scientific Advisory Board
-
-

Frecska, Ede 
Member of Medical & Scientific Advisory Board
-
-

Gutman, Howard W.
Director
-
-

Kolb, Martin 
Member of Medical & Scientific Advisory Board
-
-

Maas, Andrew 
Member of Medical & Scientific Advisory Board
-
-

Nagy, Zoltan 
Member of Medical & Scientific Advisory Board
-
-

Nutt, David John
Member of Medical & Scientific Advisory Board
-
-

Rudd, Anthony 
Member of Medical & Scientific Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Moreau, Christopher J.
CEO & Director
604.398.4175x701
-
chris@algernonpharmaceuticals.com
Kinley, James F.
Chief Financial Officer
204-995-9594
-
james@algernonpharmacuticals.com
Bryan, Christopher 
Vice President of Research & Operations
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
